Alnylam Pharmaceuticals, Inc.

Company name

Website

Start date

End date

Ticker

Listed market

NASDAQ

Country

United States of America

Business activities

Discovers, develops, and commercializes RNA interference (RNAi) therapeutics

Markets ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO for rare diseases

Head office

Cambridge, Massachusetts, United States

Chief executive

Yvonne Greenstreet

Employees (non-consolidated)

Employees (consolidated)

Related companies

Company name

Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder

Relationship graph

History

2 entries

Date	Description
2002
2022-01

News

+ Loaded when opened

Data sources

News pages

Own domain

✅

Last updated

2026-09-21 18:15 (Model: )